

## **News Release**

# Suven Revenue down by 4.96%; PAT down by 28.34% for the Third quarter ended December, 2015

**HYDERABAD, INDIA (12 Feb' 2016)** – SUVEN LIFE Sciences Limited, a biopharmaceutical company specialized in drug discovery and developmental activities in Central Nervous System disorders, today announced its Un-audited financial results for the quarter ended 31st December 2015. The un-audited financial results were reviewed by the audit committee and approved by the Board of Directors in their meeting held on 12th Feb' 2016 at Hyderabad.

# Financial Highlights for the 3<sup>rd</sup> Quarter ended December' 2015 (QoQ):

Growth in revenue INR 1165 Mn vs Rs 1226 Mn - down by 4.96% Growth in PAT INR 177 Mn vs. Rs 247 Mn - down by 28.34% Growth in EBIDTA INR 286 Mn vs. Rs 365 Mn - down by 21.67%

## Financial Highlights for the 9 months' period ended December' 2015:

Growth in revenue INR 3451 Mn vs Rs 4150 Mn - down by 16.84% Growth in PAT INR 627 Mn vs. Rs 918 Mn - down by 31.72% Growth in EBIDTA INR 952 Mn vs. Rs 1415 Mn - down by 32.70%

Suven's thrust on innovative R&D in Drug Discovery continues with a spending of INR 462 Mn (13.38% on revenue) for the 9 months' period ended Dec' 2015.

#### For more information on Suven please visit our Web site at http://www.suven.com

#### Risk Statement:

Except for historical information, all of the statements, expectations and assumptions, including expectations and assumptions, contained in this news release may be forward-looking statements that involve a number of risks and uncertainties. Although Suven attempts to be accurate in making these forward-looking statements, it is possible that future circumstances might differ from the assumptions on which such statements are based. Other important factors which could cause results to differ materially including outsourcing trends, economic conditions, dependence on collaborative partnership programs, retention of key personnel, technological advances and continued success in growth of sales that may make our products/services offerings less competitive;